The merger of Calyx and Invicro has culminated in the launch of a new corporate entity, Perceptive, marking a significant development in the biopharmaceutical services sector. This rebranding reflects the organisation’s enhanced capabilities in providing comprehensive support throughout the drug development lifecycle.

Perceptive emerges from the union of two established players in the field, bringing together over five decades of combined experience. The new entity aims to solidify its position as a global leader in discovery, imaging, and eClinical solutions for pharmaceutical, biotech, and clinical research organisations.

The company’s service portfolio spans the entire research and development spectrum, from early-stage discovery and preclinical work through to clinical trials and post-marketing studies. Perceptive’s offerings encompass imaging biomarkers, core lab services, and advanced technologies for randomisation and trial supply management (RTSM), as well as analytics and software solutions.

Comprehensive support across the R&D continuum

Perceptive’s operations are structured around three primary areas of focus, each addressing critical stages of the drug development process:

Discovery services: The Perceptive Discovery division concentrates on the early phases of drug development. It aims to assist researchers in identifying promising candidate compounds whilst minimising risk as projects progress towards clinical trials. This arm of the business offers collaborative approaches to preclinical and first-in-human imaging services, leveraging the company’s expertise to support informed decision-making.
eClinical solutions: Under the banner of Perceptive eClinical, the company provides technologies and services designed to optimise patient and clinical supply management. This division emphasises the integration of expertise, innovation, and agility to streamline clinical trial operations and enhance efficiency.

Imaging capabilities: Perceptive Imaging focuses on supporting the advancement of novel therapies through the application of scientific and regulatory expertise, coupled with global operational experience. This division aims to facilitate the generation of high-quality data across clinical trials of varying scales, with a particular emphasis on efficiency and consistency.

David Herron, CEO of Perceptive

Track record and therapeutic focus

The newly formed Perceptive brings with it a substantial track record in clinical research support. The company reports involvement in nearly 12,000 clinical trials to date, contributing to over 800 regulatory approvals.
While its experience spans all clinical phases and therapeutic areas, Perceptive highlights particular expertise in oncology and neuroscience research.

David Herron, CEO of Perceptive, commented on the launch: “Today marks a major milestone for Perceptive, as we advance our mission to serve science. We are committed to delivering the diligence, drive, and innovation today that will enable the global clinical research community to realize tomorrow’s new therapies.”

Perceptive enters the market with an established global presence, maintaining operations across the United States, Europe, and Asia. The company articulates a set of guiding values centred on customer-centricity, quality, and accountability. These principles underpin its approach to serving the biopharmaceutical industry, with a stated aim of bringing new insights and understanding to the research and development process.